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Abstract 
The pharmaceutical research and development process only begin if the drug holds the promise of being 
profitable. In the past pharmaceutical companies aimed to find solutions for common diseases with high 
prevalence. Meanwhile, the unmet medical need did not decrease in several therapeutic areas. 
Public policy makers had to encourage pharmaceutical companies to invest in research and development 
in areas with high unmet medical need. Several public measures (including financing initiatives) were 
introduced. In this paper, we focus on the public research and development and regulatory incentives to 
accelerate investment. 
In the past decades, there has been a considerable increase in public funding in the European Union, 
which diverted the attention of innovators to areas with public priorities. Still, there are areas where public 
funding alone could not lead to a prompt solution.  
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Background 
In a world impacted by COVID-19 it is not necessary to emphasise the importance of pharmaceutical 
research and development (R&D). Developing solutions to such an impactful health challenge requires 
extraordinary commitment along with substantial human and financial resources.  
Still, screening around 10,000 target molecules is needed to find one that would be available to patients1. 
The costs of drug development are enormous, considering the sunk costs of unsuccessful drug development 
phases. The estimated cost of developing a drug (including sunk costs) is in the range of 1 to 4 billion USD 
according to different studies.2 3 Hence, it is not surprising that the focus of pharmaceutical drug 
development has shifted during the last decades. 
 
Shifting focus in pharmaceutical R&D 
                                                          
1 https://www.magyosz.org/hu/oldal/gyogyszerfejlesztes (2021.03.20.) 
2 Wouters et al (2020) 
3 PricewaterhouseCoopers (PwC) (2012) 
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In the past, pharmaceutical companies aimed to explore solutions for common diseases with high 
prevalence, which reduced the financial risks of drug development, but required strong promotional 
activities to maximize profit. This approach is often called as the ‘blockbuster therapy’ era of pharmaceutical 
R&D, because even relatively small market share in a large patient population could result in more than one 
billion USD of annual sales (which is the threshold of blockbuster medicines). 
Figure 1 shows that the justifiable price determined by the economic value and disease rarity are 
inversely proportional. In the past, therapies were designed to reach blockbuster status in diseases with large 
population in Western countries in the majority of cases with minor added clinical value. Consequently, the 
unmet medical need did not decrease in rare diseases, small subgroups of more common diseases (e.g. 
patients with antimicrobial resistance in infectious diseases) or diseases in developing countries (e.g. 
malaria). The return on investment was less in these niche areas.  
 
 
Figure 1. Shift in pharmaceutical R&D in the dimension of population size and economic value 
 
In the private sector, the decision of investing into the development of a new drug candidate is a business 
decision, the pharmaceutical R&D process only begins if the drug holds the promise of being profitable, in 
other words, only if the project has positive net present value.  
As the unmet medical need was typically higher in diseases with small population sizes, public policy 
makers had to encourage investment to pharmaceutical companies. This resulted in several public incentives 
in the most important markets. The initial R&D phase could be supported by public research grants and the 
establishment of supporting platforms, such as patient registries. Regulatory incentives were provided by 
several measures, such as granting extended market exclusivity, easing standard regulatory requirements, 
accelerating regulatory procedures, reducing regulatory fees, and providing assistance in designing clinical 
trial protocols. In the pricing and reimbursement decisions, automated reimbursement status, special 
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reimbursement categories, or higher willingness-to-pay threshold for one unit of health gain support the 
market access of new medicines in neglected diseases. In this paper, we focus on the public R&D and 
regulatory incentives to accelerate investment in areas with high unmet medical needs. 
 
Public incentives to facilitate pharmaceutical R&D in rare diseases 
A legal framework that revolutionized pharmaceutical R&D in rare diseases is the Orphan Drug Act 
introduced in the USA in 1983. The Orphan Drug Act provided financial incentives, including a seven-year 
period of market exclusivity and tax credits up to 50% of R&D expenses to pharmaceutical companies who 
developed a drug for rare diseases. The definition of rare disease was defined as a disease affecting less than 
200,000 people in the USA. Following this Act, by 1990, the U.S. Food and Drug Administration (FDA) 
designated 370 products for orphan status. By 2002, the number of orphan designations increased to almost 
1,100. 4  
The European legal framework followed the American legislation and laid down the basic principles 
and stimulated orphan drug development in 2000. The European Union (EU) set multiple criteria for orphan 
designation, including:  
 a treatment, prevention or diagnosis of a life-threatening or chronically debilitating disease, 
 the prevalence of the condition in the EU is less than 5 in 10,000, or it is unlikely that marketing 
the medicine would generate sufficient return on investment due to the small population size, 
 no satisfactory method of diagnosis, prevention, or treatment is available, or the new medicine 
results in significant benefit to patients 5. 
The EU introduced several regulatory incentives, such as protocol assistance, or market exclusivity for 
a period of 10 years. In addition, there is a wide range of research grants in rare diseases by the European 
Commission. Figure 2 shows how the EU measures facilitated the orphan medicinal product authorisation 
at the European Medicines Agency (EMA). The number of authorised orphan drugs has been increasing 
since 2000.  
The example of the Orphan Drug Act and the following EU legal framework proved that public 
initiatives can help fill the gaps of purely market-based solutions in pharmaceutical R&D. 
 
                                                          
4 https://www.fda.gov/industry/orphan-products-development-events/story-behind-orphan-drug-act (2021.03.20.) 
5 https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview (2021.03.20.) 
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Figure 2. Authorised orphan medicinal products by EMA from 2000 to 20206 
 
An example of a prevailing challenge 
Pharmaceutical R&D successfully provided solutions to the majority of bacterial infections in the ’80s 
and ’90s. The availability of cheap generic medicines prevented pharmaceutical companies from investing 
into new classes of antibiotics, consequently, antimicrobial resistance has become an emerging health 
challenge. The annual public EU investment into antibiotic R&D was 147 million EUR between 2007 and 
2013, while the USA invested 260 million USD in 2015. As for the private investment, global venture 
capital in antimicrobial R&D plummeted by 28% between the two five-year periods of 2004-2008 and 2009-
2013. 7 
In response to this trend, many public incentives were introduced to facilitate companies conducting 
R&D in the field of antibiotics. In 2016, there were 58 active R&D initiatives globally that directly 
subsidized antibiotics development.8 Still, despite the numerous incentive opportunities, the issue of 
antimicrobial resistance is an emerging issue.  
 
Triumph of public financing in pandemic control 
 
The Ebola virus outbreak in West Africa in 2014 was the largest one recorded in history infecting 30,000 
people by 2016 and causing the death of 11,000 people.9 It put the spotlight on the importance of R&D in 
neglected diseases of low-income regions.  
 
The total research funding for Ebola and Marburg virus was 1.035 billion USD, 42.0% of which was 
disbursed in 2014 and 2015 during the outbreak of the virus. The following graph summarizes the sources 
of investment in Ebola research funding.  
 
                                                          
6 Orphan Medicines Figures 2000- 2020 (europa.eu) (2021.03.20.) 
7 RENWICK, MATTHEW J et al (2016) 
8 RENWICK, MATTHEW J et al (2016) 
9 FITCHETT JR ET AL (2016) 
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The total funding is divided into three categories:  
 public (e.g. National Institutes of Health, European Commission)  
 philanthropic (e.g. Gates Foundation, Wellcome Trust),  
 public-private partnership (PPP) [e.g. Innovative Medicines Initiative].10 
 
 
Figure 3. Funding awarded to Ebola research from 1997 to 2015 divided by the source of funding11 
 
Ebola could not be stopped without public-private partnership, which indicates the importance of public 
interventions to provide answers to societal challenges.  
 
European public grants 
The European Union has dedicated Framework Programmes to R&D with a growing budget since 1984. 
The 7th Framework Programme (FP7) represented a new level of funding, as its budget was over EUR 50 
billion, EUR 6 billion of which was dedicated to health R&D. 12 
A recent study showed that approximately 80% of funded Health projects in FP7 lack evaluation. Hence, 
the EU introduced a program to capture the results of the projects funded by the initiatives.13 
 
Horizon 2020 became the largest ever publicly financed research programme. The budget was almost 
EUR 80 billion throughout the 7-year cycle (2014-2020). 38.5% (EUR 29.68 billion) of the overall budget 
targeted societal challenges, among which health, demographic change, and wellbeing represented the 
highest proportion. 14 
                                                          
10 https://www.imi.europa.eu/projects-results/project-factsheets?programmes=ebola (2021.03.11) 
11 FITCHETT JR et al. (2016) 
12 https://ec.europa.eu/research/fp7/pdf/fp7-inbrief_en.pdf (2021.03.11.) 
13 https://cordis.europa.eu/project/id/733266 (2021.03.11.) 
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4. Figure EU Framework Programme budget from 1983 to 202015 
 
The Innovative Medicines Initiative (IMI) is an example of how public-private partnership can provide 
incentives to market-based solutions in areas with public importance. IMI is financed by the European Union 
(represented by the European Commission) and the European pharmaceutical industry (represented by the 
European Federation of Pharmaceutical Industries and Associations). The budget of the first IMI programme 
(IMI1) was EUR 2 billion between 2008 and 2013. During that time, it was the most significant PPP. The 
IMI2 programme ran with an extended budget of EUR 3.3 billion from 2014 to 2020.  
Besides the budget increase, it is important to note that during the IMI2 programme, other life sciences 
organisations also had the chance to contribute to the funding as associated partners. The IMI programme 
budgets were available to universities, research organisations, patient organisations, and small and medium-
sized enterprises (SME). 16 
 
The objective of IMI is to develop the next generation of vaccines, medicines, and treatment, such as 
new antibiotics or treatment to rare diseases. The IMI plays an essential role in facilitating research on fields 
where stand-alone organisations or companies would not start research due to the lack of resources, 
anticipated profit level, etc. The strategic research agenda of the IMI focuses on ‘priority disease areas, 
where safe, effective treatments are lacking, and/or where the impact on public health is greatest’.17 
 
The projects funded by the IMI stimulate the cooperation between international organisations and 
corporations. By 2021, 167 projects were started, to which more than 5,000 participants contributed. 18 
The below graph summarizes the funding provided via the IMI1 and IMI2 funds, divided by regions. 
 
                                                          
15 untitled (europa.eu) (2021.03.11.) 
16 https://www.imi.europa.eu/about-imi/imi-funding-model (2021.03.25.) 
17 https://www.imi.europa.eu/about-imi/strategic-research-agenda (2021.03.25.) 
18 https://www.imi.europa.eu/ (2021.03.25.) 
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Figure 5. IMI project budgets across Europe19 
 
Based on this figure, the vast majority of funding is spent in wealthier Western-European countries. This 
trend is in line with the landscape of other EU programmes. Healthcare-related FP7 and H2020 research 
funds were disproportionally allocated to the EU-15 versus the EU-13, as 96.9% of the total healthcare 
grants were assigned to EU-15 countries.20 This leads to the conclusion that a higher burden of disease 
(common in Eastern European countries) is not in correlation with distributing more research funding in 
these countries. 
 
The next EU funding programme would be Horizon Europe. Its budget – being EUR 95.5 billion – is 
even higher than that of Horizon 2020. Pillar II covers Global challenges and European Industrial 
Competitiveness, including the Health area. Its proposed budget is EUR 52.7 billion. The key areas of 
planned interventions include: 
 health across life span, 
 non-communicable and rare diseases, 
 personalised medicine, 
 infectious diseases, including neglected and poverty-related diseases, etc.21  
 
                                                          
19 https://www.imi.europa.eu/projects-results/maps-statistics (2021.03.25.) 
20 KALÓ et al. (2019) 
21 horizon_europe_en_investing_to_shape_our_future.pdf (europa.eu) (2021.03.11.) 
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Among Research & Innovation mission areas, cancer is highlighted22. The EU’s mission is to save 3 
million lives and to ensure longer and better living in connection with cancer by 2030. A mission is a set of 
actions across disciplines to achieve a goal within a specified timeframe, while making an impact on the 
society. In terms of the Mission on Cancer, equitable access, prevention, and optimised diagnostics are the 
essential tools to reach the goal.23  
Health innovations are considered as key among industrialized European partnerships. For such 
partnerships, commitment to financial and in-kind contribution is essential.  
The aim of Horizon Europe is to make a comprehensive impact in several areas, not only in science, but 
also in the economy and the society. Table 1 summarizes the main attributes in the different fields where 
the EU wants to make an impact via Horizon Europe. 
 
SCIENTIFIC IMPACT SOCIETAL IMPACT ECONOMIC IMPACT 
Creating high-quality new 
knowledge 
Addressing EU policy 
priorities & global 
challenges through R&I 
Generating innovation-
based growth 
Strengthening human capital 
in R&I 
Delivering benefits & 
impact via R&I missions 
Creating more and better 
jobs 
Fostering diffusion of 
knowledge and Open Science 
Strengthening the uptake of 
R&I in society 
Leveraging investments in 
R&I 
Table 1. Key impact pathways in Horizon Europe24 
 
Conclusion 
In the past decades, there has been a considerable increase in public funding for pharmaceutical R&D 
in the European Union, which diverted the attention of innovators to areas with public priorities.  
However, the problem of antimicrobial resistance indicates that there are areas where public funding 
alone could not lead to a prompt solution. In such situations, a broad range of public incentives may provide 
better solution, just like in the case of orphan medicines. 
Besides the better coordination of parallel public research funding, the methods of allocating research 
funds should be also revised. As the burden of disease is higher in Eastern European countries, involving 
organisations from these countries to defeat public health challenges would be essential in the future.  
 
"Prepared with the professional support of the Doctoral Student Scholarship Program of the Co-operative 
Doctoral Program of the Ministry of Innovation and Technology financed from the National Research, 
Development and Innovation Fund." 
 
                                                          
22 Mission area: Cancer | European Commission (europa.eu) (2021.03.11.) 
23 Conquering cancer - Publications Office of the EU (europa.eu) (2021.03.11.) 
24 horizon_europe_en_investing_to_shape_our_future.pdf (europa.eu) (2021.03.20.) 
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